Polydatin attenuates AGEs-induced upregulation of fibronectin and ICAM-1 in rat glomerular mesangial cells and db/db diabetic mice kidneys by inhibiting the activation of the SphK1-S1P signaling pathway

Molecular and Cellular Endocrinology

Volumn 427, Issue , 2016, Pages 45-56

  Chen, Cheng ^a   Huang, Kaipeng ^a   Hao, Jie ^b   Huang, Junying ^a   Yang, Zhiying ^a   Xiong, Fengxiao ^a   Liu, Peiqing ^a   Huang, Heqing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Diabetic nephropathy; Fibronectin; Intercellular adhesion molecule 1; Polydatin; Sphingosine kinase 1

Indexed keywords

ADVANCED GLYCATION END PRODUCT; FIBRONECTIN; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; PICEID; PROTEIN C FOS; PROTEIN C JUN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; TRANSCRIPTION FACTOR AP 1; ANTIDIABETIC AGENT; GLUCOSIDE; HERBACEOUS AGENT; LYSOPHOSPHOLIPID; PHOSPHOTRANSFERASE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DNA BINDING; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; KIDNEY PARENCHYMA; MESANGIUM CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; FEMALE; HUMAN; MALE; MESANGIUM; METABOLISM; MOUSE; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DRUGS, CHINESE HERBAL; FEMALE; FIBRONECTINS; GLOMERULAR MESANGIUM; GLUCOSIDES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPOGLYCEMIC AGENTS; INTERCELLULAR ADHESION MOLECULE-1; LYSOPHOSPHOLIPIDS; MALE; MICE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SPHINGOSINE; STILBENES; UP-REGULATION;

EID: 84962532433     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2016.03.003     Document Type: Article

References (68)

1. Bode C., Graler M.H. Quantification of sphingosine-1-phosphate and related sphingolipids by liquid chromatography coupled to tandem mass spectrometry. Methods Mol. Biol. 2012, 874:33-44.
2. Chen L., Lan Z., Lin Q., Mi X., He Y., Wei L., Lin Y., Zhang Y., Deng X. Polydatin ameliorates renal injury by attenuating oxidative stress-related inflammatory responses in fructose-induced urate nephropathic mice. Food Chem. Toxicol. 2013, 52:28-35.
3. Chen S., Khan Z.A., Cukiernik M., Chakrabarti S. Differential activation of NF-κB and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E1089-E1097.
4. Dronavalli S., Duka I., Bakris G.L. The pathogenesis of diabetic nephropathy. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4:444-452.
5. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev. 2002, 23:599-622.
6. Fukami K., Ueda S., Yamagishi S., Kato S., Inagaki Y., Takeuchi M., Motomiya Y., Bucala R., Iida S., Tamaki K., Imaizumi T., Cooper M.E., Okuda S. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int. 2004, 66:2137-2147.
7. Galkina E. Leukocyte recruitment and vascular injury in diabetic nephropathy. J. Am. Soc. Nephrol. 2006, 17:368-377.
8. Gasparitsch M., Arndt A., Pawlitschek F., Oberle S., Keller U., Kasper M., Bierhaus A., Schaefer F., Weber L.T., Lange-Sperandio B. RAGE-mediated interstitial fibrosis in neonatal obstructive nephropathy is independent of NF-κB activation. Kidney Int. 2013, 84:911-919.
9. Geoffroy K., Wiernsperger N., Lagarde M., El Bawab S. Bimodal effect of advanced glycation end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous sphingolipids. J. Biol. Chem. 2004, 279:34343-34352.
10. Geoffroy K., Troncy L., Wiernsperger N., Lagarde M., Bawab S.E. Glomerular proliferation during early stages of diabetic nephropathy is associated with local increase of sphingosine-1-phosphate levels. FEBS Lett. 2005, 579:1249-1254.
11. Guh J., Huang J., Chen H., Hung W., Lai Y., Chuang L. Advanced glycation end product-induced proliferation in NRK-49F cells is dependent on the JAK2/STAT5 pathway and cyclin D1. Am. J. Kidney Dis. 2001, 38:1096-1104.
12. Guo B., Koya D., Isono M., Sugimoto T., Kashiwagi A., Haneda M. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004, 53:200-208.
13. Hagiwara S., McClelland A., Kantharidis P. MicroRNA in diabetic nephropathy: renin angiotensin, age/RAGE, and oxidative stress pathway. J. Diabet. Res. 2013, 2013:1-11.
14. Heo K., Park K., Kim Y., Kim S., Oh Y., Kim I., Ryu S.H., Suh P. Sphingosine 1-phosphate induces vesicular endothelial growth factor expression in endothelial cells. BMB Rep. 2009, 42:685-690.
15. Hsieh H., Sun C., Wu C., Wu C., Tung W., Wang H., Yang C. Sphingosine 1-phosphate induces EGFR expression via Akt/NF-κB and ERK/AP-1 pathways in rat vascular smooth muscle cells. J. Cell. Biochem. 2008, 103:1732-1746.
16. Hsu C., Lee I., Lin C., Hsiao L., Yang C. Sphingosine-1-phosphate mediates COX-2 expression and PGE. J. Cell. Physiol. 2015, 230:702-715.
17. Huang J., Huang K., Lan T., Xie X., Shen X., Liu P., Huang H. Curcumin ameliorates diabetic nephropathy by inhibiting the activation of the SphK1-S1P signaling pathway. Mol. Cell. Endocrinol. 2013, 365:231-240.
18. Huang K., Huang J., Xie X., Wang S., Chen C., Shen X., Liu P., Huang H. Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-β1 by activating the Nrf2/ARE pathway in glomerular mesangial cells. Free Radic. Biol. Med. 2013, 65:528-540.
19. Huang K., Huang J., Chen C., Hao J., Wang S., Huang J., Liu P., Huang H. AP-1 regulates sphingosine kinase 1 expression in a positive feedback manner in glomerular mesangial cells exposed to high glucose. Cell. Signal. 2014, 26:629-638.
20. Huang K., Chen C., Hao J., Huang J., Wang S., Liu P., Huang H. Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-induced upregulation of fibronetin and transforming growth factor-β1 in rat glomerular messangial cells. Mol. Cell. Endocrinol. 2015, 399:178-189.
21. Hummel K.P., Dickie M.M., Coleman D.L. Diabetes, a new mutation in the mouse. Science 1966, 153:1127-1128.
22. Ichinose K., Kawasaki E., Eguchi K. Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am. J. Nephrol. 2007, 27:554-564.
23. Ikeda M., Ikeda U., Takahashi M., Shimada K., Minota S., Kano S. Nitric oxide inhibits intracellular adhesion molecule-1 expression in rat mesangial cells. J. Am. Soc. Nephrol. 1996, 7:2213-2218.
24. Jiang X., Liu W., Deng J., Lan L., Xue X., Zhang C., Cai G., Luo X., Liu J. Polydatin protects cardiac function against burn injury by inhibiting sarcoplasmic reticulum Ca2+ leak by reducing oxidative modification of ryanodine receptors. Free Radic. Biol. Med. 2013, 60:292-299.
25. Jochum W., Passegu E., Wagner E.F. AP-1 in mouse development and tumorigenesis. Oncogene 2001, 20:2401-2412.
26. Kanwar Y.S., Sun L., Xie P., Liu F., Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu. Rev. Pathol. Mech. Dis. 2011, 6:395-423.
27. Kim K.H., Kim Y., Gubler M.C., Steffes M.W., Lane P.H., Kashtan C.E., Crosson J.T., Mauer S.M. Structural-functional relationships in Alport syndrome. J. Am. Soc. Nephrol. 1995, 5:1659-1668.
28. Korrapati M.C., Howell L.H., Shaner B.E., Megyesi J.K., Siskind L.J., Schnellmann R.G. Suramin: a potential therapy for diabetic nephropathy. PLoS One 2013, 8:e73655.
29. Kyriakis J.M., Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-Year update. Physiol. Rev. 2012, 92:689-737.
30. Lan T., Bi H., Xu S., Le K., Xie Z., Liu Y., Huang H. Determination of sphingosine kinase activity in biological samples by liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr. 2010, 24:1075-1083.
31. Lan T., Shen X., Liu P., Liu W., Xu S., Xie X., Jiang Q., Li W., Huang H. Berberine ameliorates renal injury in diabetic C57BL/6 mice: involvement of suppression of SphK-S1P signaling pathway. Archiv. Biochem. Biophys. 2010, 502:112-120.
32. Lan T., Liu W., Xie X., Xu S., Huang K., Peng J., Shen X., Liu P., Wang L., Xia P., Huang H. Sphingosine Kinase-1 pathway mediates high glucose-induced fibronectin expression in glomerular mesangial cells. Mol. Endocrinol. 2011, 25:2094-2105.
33. Lenz O., Fornoni A., Ijaz A., Tejada T. Role of inflammation in diabetic nephropathy. Curr. Diabet. Rev. 2008, 4:10-17.
34. Liebisch M., Bondeva T., Franke S., Daniel C., Amann K., Wolf G. Activation of the receptor for advanced glycation end products induces nuclear inhibitor of protein phosphatase-1 suppression. Kidney Int. 2014, 86:103-117.
35. Lin C., Lee I., Hsu C., Hsu C., Chi P., Hsiao L., Yang C. Sphingosine-1-phosphate mediates ICAM-1-dependent monocyte adhesion through p38 MAPK and p42/p44 MAPK-dependent akt activation. Plos One 2015, 10:e0118473.
36. Liu R., Zhong Y., Li X., Chen H., Jim B., Zhou M.M., Chuang P.Y., He J.C. Role of transcription factor acetylation in diabetic kidney disease. Diabetes 2014, 63:2440-2453.
37. Liu W., Lan T., Xie X., Huang K., Peng J., Huang J., Shen X., Liu P., Huang H. S1P2 receptor mediates sphingosine-1-phosphate-induced fibronectin expression via MAPK signaling pathway in mesangial cells under high glucose condition. Exp. Cell Res. 2012, 318:936-943.
38. Maceyka M., Harikumar K.B., Milstien S., Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012, 22:50-60.
39. Mason R.M. Extracellular matrix metabolism in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14:1358-1373.
40. Miyatake N., Shikata K., Sugimoto H., Kushiro M., Shikata Y., Ogawa S., Hayashi Y., Miyasaka M., Makino H. Intercellular adhesion molecule 1 mediates mononuclear cell infiltration into rat glomeruli after renal ablation. Nephron 1998, 79:91-98.
41. Ogretmen B., Hannun Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer 2004, 4:604-616.
42. Okada S., Shikata K., Matsuda M., Ogawa D., Usui H., Kido Y., Nagase R., Wada J., Shikata Y., Makino H. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003, 52:2586-2593.
43. Park C.W. Diabetic kidney disease: from epidemiology to clinical perspectives. Diabet. Metab. J. 2014, 38:252.
44. Peppa M., Brem H., Cai W., Zhang J., Basgen J., Li Z., Vlassara H., Uribarri J. Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). Am. J. Nephrol. 2006, 26:430-436.
45. Peters V., Schmitt C. Murine models of diabetic nephropathy. Exp. Clin. Endocrinol. Diabetes 2012, 120:191-193.
46. Pitson S.M., Moretti P.A., Zebol J.R., Lynn H.E., Xia P., Vadas M.A., Wattenberg B.W. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 2003, 22:5491-5500.
47. Pitson S.M. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem. Sci. 2011, 36:97-107.
48. Raij L., Azar S., Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int. 1984, 26:137-143.
49. Raivich G., Behrens A. Role of the AP-1 transcription factor c-Jun in developing, adult and injured brain. Prog. Neurobiol. 2006, 78:347-363.
50. Riser B.L., Cortes P., Heilig C., Grondin J., Ladson-Wofford S., Patterson D., Narins R.G. Cyclic stretching force selectively up-regulates transforming growth factor-beta isoforms in cultured rat mesangial cells. Am. J. Pathol. 1996, 148:1915-1923.
51. Rivière C., Delaunay J., Immel F., Cullin C., Monti J. The polyphenol piceid destabilizes preformed amyloid Fibrils and oligomers in vitro: hypothesis on possible molecular mechanisms. Neurochem. Res. 2009, 34:1120-1128.
52. Sanchez A.P., Sharma K. Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev. Mol. Med. 2009, 11:e13.
53. Sasaki T., Kojima H., Kishimoto R., Ikeda A., Kunimoto H., Nakajima K. Spatiotemporal regulation of c-Fos by ERK5 and the E3 ubiquitin ligase UBR1, and its biological role. Mol. Cell 2006, 24:63-75.
54. Schena F.P. Pathogenetic mechanisms of diabetic nephropathy. J. Am. Soc. Nephrol. 2005, 16:S30-S33.
55. Schlondorff D., Banas B. The mesangial cell revisited: no cell is an Island. J. Am. Soc. Nephrol. 2009, 20:1179-1187.
56. Sharma K., McCue P., Dunn S.R. Diabetic kidney disease in the db/db mouse. Am. J. Physiol. Ren. Physiol. 2003, 284:F1138-F1144.
57. Shimizu H., Hori Y., Kaname S., Yamada K., Nishiyama N., Matsumoto S., Miyata K., Oba M., Yamada A., Kataoka K., Fujita T. siRNA-based therapy ameliorates glomerulonephritis. J. Am. Soc. Nephrol. 2010, 21:622-633.
58. Spiegel S., Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. 2003, 4:397-407.
59. Sugimoto H., Shikata K., Hirata K., Akiyama K., Matsuda M., Kushiro M., Shikata Y., Miyatake N., Miyasaka M., Makino H. Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes 1997, 46:2075-2081.
60. Takuwa N., Ohkura S.I., Takashima S.I., Ohtani K., Okamoto Y., Tanaka T., Hirano K., Usui S., Wang F., Du W., Yoshioka K., Banno Y., Sasaki M., Ichi I., Okamura M., Sugimoto N., Mizugishi K., Nakanuma Y., Ishii I., Takamura M., Kaneko S., Kojo S., Satouchi K., Mitumori K., Chun J., Takuwa Y. S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. Cardiovasc. Res. 2010, 85:484-493.
61. Tesch G.H., Lim A.K.H. Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. AJP Ren. Physiol. 2011, 300:F301-F310.
62. Wang L. Activation of the sphingosine kinase-signaling pathway by high glucose mediates the proinflammatory phenotype of endothelial cells. Circulation Res. 2005, 97:891-899.
63. Wong L., Tan S.S.L., Lam Y., Melendez A.J. Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases. J. Med. Chem. 2009, 52:3618-3626.
64. Xie J., Méndez J.D., Méndez-Valenzuela V., Aguilar-Hernández M.M. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell. Signal. 2013, 25:2185-2197.
65. Xie X., Peng J., Huang K., Huang J., Shen X., Liu P., Huang H. Polydatin ameliorates experimental diabetes-induced fibronectin through inhibiting the activation of NF-κB signaling pathway in rat glomerular mesangial cells. Mol. Cell. Endocrinol. 2012, 362:183-193.
66. Xin C., Ren S., Kleuser B., Shabahang S., Eberhardt W., Radeke H., Schafer-Korting M., Pfeilschifter J., Huwiler A. Sphingosine 1-phosphate cross-activates the smad signaling cascade and mimics transforming growth factor-beta-induced cell responses. J. Biol. Chem. 2004, 279:35255-35262.
67. Xing W., Wu J., Jia M., Du J., Zhang H., Qin L. Effects of polydatin from Polygonum cuspidatum on lipid profile in hyperlipidemic rabbits. Biomed. Pharmacother. 2009, 63:457-462.
68. Yaghobian D., Don A.S., Yaghobian S., Chen X., Saad S., Pollock C. Increased Sphingosine 1-phosphate mediates inflammation and fibrosis in tubular injury in diabetic nephropathy. Clin. Exp. Pharmacol. Physiology 2015, 43:56-66.